...BCIQ: BioCentury Online Intelligence Company Compound Phase Indication Palobiofarma S.L. / Novartis AG (NYSE:NVS; SIX:NOVN) PBF-509...

...and safety of the nanoparticle conjugate in various models of respiratory complications. Palobiofarma S.L. has PBF-680...

...Palobiofarma granted Novartis exclusive, worldwide rights to develop and commercialize PBF-509 . Palobiofarma said the adenosine...

...LLC (Danvers, Mass.) and obtained exclusive, worldwide rights to non-small cell lung cancer (NSCLC) candidate PBF-509...
...to disclose financial terms of the deal (see BioCentury, May 4, 2015) . Palobiofarma said PBF-509...

...According to ClinicalTrials.gov, Palobiofarma S.L. in July started a Phase I trial of A2A antagonist PBF-509...